Work

Supplementary Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

Year: 2023

Type: supplementary-materials

Abstract: Definition of Progression, Tumor Classification, and Eligibility Criteria, retreatment criteria

DOI: 10.1158/2767-9764.22545915

Authors: Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Jing Li, Diane Durecki, Jan Drappatz, Vinay Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, S. Percy Ivy, Ranjit S. Bindra, Antonio Omuro, Patricia LoRusso

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362548514

Cites:

Cited by:

Related to: 10